Claims for Patent: 4,521,431

Summary for Patent: 4,521,431

Title:	Aminoalkyl furan derivative
Abstract:	A novel crystal form of ranitidine (N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl-N'-methyl-2- nitro-1,1-ethenediamine) hydrochloride, designated Form 2, and having favorable filtration and drying characteristics, is characterized by its infra-red spectrum and/or by its x-ray powder diffraction patterns.
Inventor(s):	Crookes; Derek L. (Hertford, GB2)
Assignee:	Glaxo Group Limited (London, GB2)
Application Number:	06/406,710
Patent Claims:	1. Form 2 ranitidine hydrochloride characterised by an infra-red spectrum as a mull in mineral oil showing the following main peaks: 2. Form 2 ranitidine hydrochloride according to claim 1 further characterised by the following x-ray powder diffraction pattern expressed in terms of "d" spacings and relative intensities (1) (s=strong, m=medium, w=weak, v=very, d=diffuse) and obtained by the Debye Scherrer method in a 114.6 mm diameter camera by exposure for 12 hours to CoK.sub.a radiation and for 3 hours to CuKa radiation: 3. A pharmaceutical composition in the form of tablets comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharamceutically acceptable carrier or diluent. 4. A pharmaceutical composition in the form of tablets comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent. 5. A pharmaceutical composition in the form of capsules comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent. 6. A pharmaceutical composition in the form of capsules comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent. 7. A pharmaceutical composition in the form of a powder comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent. 8. A pharmaceutical composition in the form of a powder comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent. 9. A pharamaceutical composition in the form of lozenges comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent. 10. A pharmaceutical composition in the form of lozenges comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent. 11. A pharmaceutical composition in the form of suppositories comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent. 12. A pharmaceutical composition in the form of suppositories comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent. 13. A pharmaceutical composition in the form of retention enemas comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent. 14. A pharmaceutical composition in the form of retention enemas comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent. 15. A pharmaceutical composition in the form of an ointment comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent. 16. A pharmaceutical composition in the form of an ointment comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent. 17. A method of treating condition mediated through histamine H.sub.2 -receptors which comprises administering to a patient an effective amount of a compound as claimed in claim 1 to relieve said condition. 18. A method of treating condition mediated through histamine H.sub.2 -receptors which comprises administering to a patient an effective amount of a compound as claimed in claim 2 to relieve said condition.